Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease
https://doi.org/10.21518/2079-701X-2018-6-61-65
Abstract
The paper is devoted to the problem of clinical efficacy and pharmacoeconomic evaluation of Spiolto Respimat. The results of clinical trials prove that Spiolto Respimat in patients with COPD improves spirometric values, symptoms of dyspnea and health-related quality of life, compared with placebo, tiotropium bromide (5 μg) and olodaterol (5 μg). According to conducted in European countries pharmacoeconomic analysis «cost-utility» therapy with Spiolto Respimat results in quality-adjusted life-year gained comparing to tiotropium bromide (5 μg). Also Spiolto Respimat is an effective option of COPD therapy comparing to the other combinations of long-acting muscarinic antagonist – long-acting beta2-adrenergic agonist.
About the Authors
S. K. Zyryanov
RUDN University, Moscow;
Municipal Clinical Hospital no. 24 of the Department of Healthcare of Moscow, Moscow
Russian Federation
PhD
Russian Federation
PhD
Y. A. Galatonova
RUDN University, Moscow
Russian Federation
Russian Federation
References
1. Global Strategy for the Diagnosis, Management and prevention of Chronic Obstructive Pulmonary Disease, 2017. http://goldcopd.org/.
2. Newman SP. Inhaler treatment options in COPD. Eur Resp Rev, 2005, 14: 102–108.
3. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. Int J of COPD, 2009, 4: 381–390.
4. Spiolto Respimat 2.5 microgram/2.5 micro-gram, inhalation solution [summary of product characteristics]. 2016. http: //mri.medagencies. org/download/NL_H_3157_001_.
5. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J of Aerosol Med, 2005 September, 18(3): 273-282.
6. Ram FSF, Carvallho CR, White J. Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J Chron Obstruct Pulmon Dis, 2011, 6: 129–139.
7. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest, 1998, 113(4): 957–963.
8. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med, 2005, 18(3): 264–272.
9. Calverley PM, Könen-Bergmann M, Richard F, Bell S, Hohlfeld JM. Tiotropium Respimat Versus HandiHaler: Comparison of Broncho-dilator Efficacy of Various Doses in Clinical Trials. Adv Ther, 2016 May, 33(5): 786-93.
10. Caillaud D, Le Merre C, Martinat Y, Aguilaniu B, Pavia D. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J of COPD, 2007, 2(4): 559–565.
11. Ichinose M, Fujimoto T, Fukuchi Y. tiotropium 5microg via Respimat and 18 microg via hand-ihaler, efficacy and safety in Japanese COPD patients. Respir. Med, 2010, 104(2): 228–236.
12. Derom E, Brusselle GG, Joos GF. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD. Int J Chron Obstruct Pulmon Dis, 2016, 11: 3163-3177.
13. Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med, 2015, 109(10): 1312–1319.
14. Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther, 2015, 32: 53–59.
15. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G et al. Tiotropium and olodaterol fixed dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J, 2015, 45(4): 969–979.
16. O’Donnell D, Casabur R, De Sousa D, Xue W, Frith P, Hamiltonet A et al. Effects of 6 weeks’ treatment with once-daily tiotropium and olodaterol fixed-dose combination on inspiratory capacity and exercise endurance in patients with COPD: The Moracto™ studies. Am J Respir Crit Care Med, 2015, 191: A3972.
17. Maltais F, Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Eur Respir J, 2014, 44(Suppl 58): 238.
18. Selya-Hammer C, Gonzalez-Rojas GN, Baldwin M, Ternouth A, Miravitlles M, Maureen Rutten-van Mölken M. Development of an enhanced healtheconomic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis, 2016, 10(5): 391–401.
19. Job FM van Boven, Kocks WHJ, Postma JM. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropi-um-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis, 2016 Sep 19, 11: 2191-2201.
20. Tebboth A, Ternouth A, Gonzalez-Rojas N. UK-specific cost-effectiveness of tiotropium + olodaterol fixed dose combination versusother LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res, 2016 Nov 7, 8: 667-674.
21. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S et al. UPLIFT Study Investigators. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med, 2008, 359(15): 1543–1554.
22. Wise RA, Anzueto A, Calverley P, Dahl R, Dusser D, Pledger G, et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res, 2013, 14: 40.
Review
For citations:
Zyryanov SK, Galatonova YA. Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease. Meditsinskiy sovet = Medical Council. 2018;(6):61-65. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-61-65
Views:
2365
Email this article 